Evolution and immunopathology of chikungunya virus informs therapeutic development

Filipa Henderson Sousa, Amalina Ghaisani Komarudin, Fern Findlay-Greene, Anom Bowolaksono, R. Tedjo Sasmono, Craig Stevens, Peter G. Barlow

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is an emerging global threat identified in more than 60 countries across continents. The risk of CHIKV transmission is rising due to increased global interactions, year-round presence of mosquito vectors, and the ability of CHIKV to produce high host viral loads and undergo mutation. Although CHIKV disease is rarely fatal, it can progress to a chronic stage, during which patients experience severe debilitating arthritis that can last from several weeks to months or years. At present, there are no licensed vaccines or antiviral drugs for CHIKV disease, and treatment is primarily symptomatic. This Review provides an overview of CHIKV pathogenesis and explores the available therapeutic options and the most recent advances in novel therapeutic strategies against CHIKV infections.

Original languageEnglish
Article numberdmm049804
JournalDMM Disease Models and Mechanisms
Issue number4
Publication statusPublished - Apr 2023


  • Antiviral compounds
  • Chikungunya pathogenesis
  • Chikungunya virus
  • Immunomodulatory drugs
  • Monoclonal antibodies
  • Vaccines


Dive into the research topics of 'Evolution and immunopathology of chikungunya virus informs therapeutic development'. Together they form a unique fingerprint.

Cite this